Welcome to LookChem.com Sign In|Join Free
  • or
FMOC-DL-CHA-OH is a chemical compound that features an FMOC (9-fluorenylmethoxycarbonyl) protecting group attached to a DL-cyclohexylalanine (DL-CHA) amino acid. FMOC-DL-CHA-OH is integral in the field of peptide synthesis, where the FMOC group shields the amine group of amino acids, aiding in the purification process of peptides. DL-CHA, a chiral amino acid with a cyclohexane ring in its side chain, is known for its role in the creation of peptidomimetics and pharmaceutical compounds. FMOC-DL-CHA-OH is predominantly used in solid-phase peptide synthesis and is recognized for its potential in drug development and medical research, serving as a fundamental building block for the synthesis of bioactive peptides. It also contributes to the study of structure-activity relationships in peptide-based compounds.

188632-07-7

Post Buying Request

188632-07-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

188632-07-7 Usage

Uses

Used in Pharmaceutical Industry:
FMOC-DL-CHA-OH is used as a building block in the synthesis of bioactive peptides for various pharmaceutical applications. Its incorporation into peptide structures allows for the development of new drugs with specific therapeutic properties.
Used in Peptide Synthesis:
FMOC-DL-CHA-OH is used as a protected amino acid in solid-phase peptide synthesis, facilitating the stepwise assembly of peptide chains and enhancing the efficiency and purity of the final product.
Used in Drug Development:
FMOC-DL-CHA-OH is used as a component in the development of new drugs, particularly in the design of peptidomimetics that can mimic the action of biologically active peptides but with improved stability and bioavailability.
Used in Medical Research:
FMOC-DL-CHA-OH is used as a research tool in the study of structure-activity relationships of peptide-based compounds, aiding scientists in understanding how modifications to peptide structure can influence biological activity and therapeutic potential.

Check Digit Verification of cas no

The CAS Registry Mumber 188632-07-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,8,6,3 and 2 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 188632-07:
(8*1)+(7*8)+(6*8)+(5*6)+(4*3)+(3*2)+(2*0)+(1*7)=167
167 % 10 = 7
So 188632-07-7 is a valid CAS Registry Number.

188632-07-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name Fmoc-Cha-OH

1.2 Other means of identification

Product number -
Other names FMOC-DL-CHA-OH

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:188632-07-7 SDS

188632-07-7Downstream Products

188632-07-7Relevant academic research and scientific papers

Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2

Geistlinger, Timothy R.,Guy, R. Kiplin

, p. 6852 - 6853 (2007/10/03)

Nuclear hormone receptor (NR) signaling, currently a therapeutic target in multiple diseases, involves an ordered series of protein interactions to regulate transcription in response to changing hormone levels. Later steps in the process of ligand-dependent signaling are driven by a highly conserved interaction between the NRs and the steroid receptor coactivators (SRCs) that is effected by a conserved interaction motif (L1XXL2L3), known as an NR box. Using computational design and combinatorial chemistry, we have produced novel ∞-helical proteomimetics of the second NR box of SRC2 that exploit structural differences between human estrogen receptor ∞ (hER∞), human estrogen receptor β (hERβ), and human thyroid hormone receptor β (hTRβ). The resulting library sequentially replaced each leucine with non-natural side chains. Screening this library using a quantitative competition assay revealed compounds that selectively inhibit the interaction of SRC2-2 with each individual NR in preference to its interaction with the other NR. This approach generated highly selective compounds from one that had no specificity for a particular family member. These compounds represent the first family-member-selective competitive inhibitors of the protein interactions of transcription factors. Copyright

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 188632-07-7